VOYDEYA cpr pellic 100 mg 180(2x90) pce

7680693010048 CH-69301 L04AJ09 07.15.0.

No images available

Details

Product number
6930102
CPT
-
Packaging group
180 (2x90)
Unit
Tablette(n)
Composition
danicopanum 100 mg, hypromellosi acetas succinas, lactosum monohydricum 121 mg, cellulosum microcristallinum, carmellosum natricum conexum, natrii laurilsulfas, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), E 171, macrogolum 3350, talcum, pro compresso obducto corresp. natrium max. 2.44 mg.

Articles (1)

Voydeya 100 mg, Filmtabletten
Filmtabletten
180 (2x90)
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Professional SmPC
Allemand
05/04/2026
Professional SmPC
Français
05/04/2026
Professional SmPC
Italien
05/04/2026
Patient information leaflet
Allemand
17/03/2025
Patient information leaflet
Français
17/03/2025
Patient information leaflet
Italien
17/03/2025

Detailed composition

Substance Quantity Type Category
danicopanum
100.0 MG Substance Wirkstoff (Principe actif)
hypromellosi acetas succinas
- Substance HNIDK
lactosum monohydricum
121.0 MG Substance HBESI
cellulosum microcristallinum
- Substance HNIDK
carmellosum natricum conexum
- Substance HNIDK
natrii laurilsulfas
- Substance Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)
silica colloidalis anhydrica
- Substance HNIDK
magnesii stearas
- Substance HNIDK
poly(alcohol vinylicus)
- Substance HNIDK
E 171
- Substance FNIDK
macrogolum 3350
- Substance HNIDK
talcum
- Substance HNIDK
natrium
- Substance HBESI

Authorization holder

Alexion Pharma GmbH

6340 Baar

Authorization information

Swissmedic authorization number
69301
Drug name
Voydeya, Filmtabletten
Galenic form
FILM
ATC Code
L04AJ09
Authorization status
Z
Dispensation category
A
First authorization
30/04/2024
Authorization expiration date
29/04/2029
IT number
07.15.0.
Domain
Human medicine
Field of application
als Zusatztherapie zu Ravulizumab oder Eculizumab zur Behandlung bei klinisch relevanter extravaskulärer Hämolyse nach mindestens 6-monatiger Monotherapie mit einem C5-Inhibitor bei erwachsenen Patienten mit paroxysmaler nächtlicher Hämoglobinurie

Packaging details

Description (FR)
VOYDEYA cpr pellic 100 mg 180(2x90) pce
Description (DE)
VOYDEYA Filmtabl 100 mg 180(2x90) Stk
Market launch
30/04/2024
Narcotic (BTM)
No

Other packaging sizes

VOYDEYA 50 mg / 100 mg cpr pellic 50 mg 180(2x90)
180 (2x90) TABL
GTIN: 7680693010031
View
Buy us a coffee Explore the data